Symbiotec Pharmalab IPO aims to raise ₹1,757 crore through a combination of a fresh issue and an offer for sale. The fresh issue consists of shares worth ₹150 crore, while existing shareholders will offload shares worth ₹1,607 crore through the OFS portion. The public issue will remain open for subscription from August 24 to August 27, 2026. The company has fixed a price band of ₹938–₹988 per share, with a minimum application size of 15 shares. Upon completion of the issue process, the company’s shares are proposed to be listed on both NSE and BSE.
Symbiotec Pharmalab IPO Details
| IPO Open Date | 24-08-2026 |
| IPO Close Date | 27-08-2026 |
| Face Value | ₹2 Per Equity Share |
| IPO Price Band | ₹938 to ₹988 Per Share |
| Issue Size | Approx ₹1757 cr. |
| Fresh Issue | Approx ₹150 cr. |
| Offer For Sale | Approx 1,62,65,181 Equity Shares |
| Issue Type | Book Built Issue |
| IPO Listing | NSE,Bse |
Issue Reservation
| Investor Category | Shares Offered % |
|---|---|
| Retail Shares Offered | 35% |
| NII Shares Offered | 15% |
| QIB Shares Offered | 50% |
Symbiotec Pharmalab IPO Market Lot
The Symbiotec Pharmalab IPO minimum market lot is 15 shares with ₹14,820 application amount. The retail investors can apply up-to 13 lots with 195 shares of ₹1,92,660 amount.
| Application | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 15 | ₹14,820 |
| Retail Maximum | 13 | 195 | ₹1,92,660 |
| S-HNI Minimum | 14 | 210 | ₹2,07,480 |
| S-HNI Maximum | 67 | 1,005 | ₹9,92,940 |
| B-HNI Minimum | 68 | 1,020 | ₹10,07,760 |
Symbiotec Pharmalab IPO Anchor Investors
| Anchor Bidding Date | 21-08-2026 |
| Shares Offered | 53,25,909 Shares |
| Lock-in period end date 50% shares(30 Days) | 27-09-2026 |
| Lock-in period end date 50% shares (90 Days) | 26-11-2026 |
Symbiotec Pharmalab IPO Dates
The Symbiotec Pharmalab IPO Open date is August 24 and the close date is August 27. The Symbiotec Pharmalab IPO allotment will be finalized on August 28 and the IPO listing on September 1.
| IPO Open Date: | 24- 08-2026 |
| IPO Close Date: | 27-08-2026 |
| Basis of allotment: | 28-08-2026 |
| Refunds: | 31-08-2026 |
| Credit to Demat Account: | 31-08-2026 |
| IPO Listing Date: | 01-09-2026 |
Pre and Post-IPO Shareholding Pattern
| Category | Pre IPO | Post IPO |
|---|---|---|
| Promoter and Promoter Group | 34.47% | – |
| Public | 65.53% | – |
| Total | 100% |
Company Promoters: Anil Satwani, Kashish Satwani, Sushil Satwani and Satwani Holdings LLP.
Symbiotec Pharmalab: Key Strengths and Hidden Risks
Key Strengths
Strong Position in Pharmaceutical Manufacturing
Symbiotec Pharmalab operates in the pharmaceutical sector and specializes in manufacturing active pharmaceutical ingredients (APIs) and fermentation-based products, serving both domestic and international customers.
Established Operating History
The company has been in business since 2002, providing it with more than two decades of industry experience and customer relationships.
Global Market Presence
The company exports its products to multiple international markets, reducing dependence on a single geography and expanding its revenue opportunities.
Diversified Manufacturing Infrastructure
Symbiotec has multiple manufacturing facilities and continues to invest in expanding production capacity, which can support future growth.
Experienced Promoters and Management
The business is led by promoters and management personnel with significant experience in the pharmaceutical industry, helping drive operational and strategic decisions.
Hidden Risks
High Dependence on Regulatory Approvals
Pharmaceutical companies operate under strict regulations. Any failure to maintain regulatory standards or obtain approvals could impact operations and revenue.
Customer Concentration Risk
A significant portion of revenue may come from a limited number of customers. Loss of major clients could adversely affect business performance.
Foreign Market Exposure
A substantial part of the company’s business is linked to exports. Changes in global demand, trade policies, or currency fluctuations may affect earnings.
Industry Competition
The API and pharmaceutical manufacturing industry is highly competitive. Pricing pressure from domestic and international competitors may impact profit margins.
Execution Risk in Expansion Plans
The company is investing in capacity expansion and future projects. Delays, cost overruns, or lower-than-expected utilization could affect returns on investment.
Dependence on Raw Material Supply
Disruptions in the availability or pricing of key raw materials can increase production costs and impact profitability.
Conclusion
Symbiotec Pharmalab benefits from a long operating track record, pharmaceutical manufacturing expertise, and international business exposure. However, investors should carefully evaluate regulatory, customer concentration, competition, and expansion-related risks before making an investment decision.
Objects of the Issue
| Purpose | Crores |
|---|---|
| Repayment or prepayment, either fully or partially, of selected outstanding borrowings of the company | ₹112.50 |
| General corporate purposes | ₹- |
Symbiotec Pharmalab IPO Company Financial Report
| Period Ended | Revenue | Expense | Pat | Assets |
|---|---|---|---|---|
| 2024 | ₹723.33 | ₹590.99 | ₹100.06 | ₹1,294.79 |
| 2025 | ₹755.98 | ₹608.85 | ₹96.79 | ₹1,579.65 |
| 2026 | ₹872.26 | ₹709.90 | ₹109.90 | ₹1,780.79 |
Symbiotec Pharmalab IPO Valuation – FY2026
Check Symbiotec Pharmalab IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
|---|---|
| ROE | 11.19% |
| ROCE | 11.56% |
| EBITDA Margin | 26.59% |
| PAT Margin | 12.60% |
| Debt to equity ration | – |
| Earning Per Share(EPS) | ₹19.10 |
| P/E Ratio | N/A |
| Return on Net Worth (RoNW) | 9.48% |
| Net Asset Value(NAV) | ₹184.69 |
About
Symbiotec Pharmalab Limited is an Indian pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients (APIs), fermentation-based products, and specialty pharmaceutical solutions. Established in 2002 and headquartered in Indore, Madhya Pradesh, the company serves customers across domestic and international markets through its manufacturing and research capabilities.
Over the years, Symbiotec Pharmalab has built expertise in complex pharmaceutical ingredients and process development, focusing on quality, regulatory compliance, and operational efficiency. The company operates multiple manufacturing facilities and caters to a diverse customer base within the healthcare and pharmaceutical industries.
The company is backed by experienced promoters and management professionals who have contributed to its growth and expansion. Through continuous investment in technology, product development, and manufacturing infrastructure, Symbiotec Pharmalab aims to strengthen its position in the global pharmaceutical value chain.
With a focus on innovation, quality standards, and long-term business growth, Symbiotec Pharmalab continues to expand its product portfolio and enhance its presence in regulated and emerging markets worldwide.
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income (cr.) |
|---|---|---|---|---|---|
| Concord Biotech Ltd | 24.78 | 61.07 | 14% | – | 1,054.90 |
| Divi’s Laboratories Ltd | 96.75 | 87.80 | 16.50% | 631 | 10,560 |
| Cohance Lifesciences Ltd | 4.69 | 95.02 | 7% | – | 2,268.55 |
| Laurus Labs Ltd | 16.47 | 109.36 | 16.80% | – | 6,812.90 |
Symbiotec Pharmalab IPO Lead Managers aka Merchant Bankers
- JM Financial Ltd.
- Avendus Capital Pvt. Ltd.
- Motilal Oswal Investment Advisors Ltd.
- Nomura Financial Advisory & Securities (India) Pvt. Ltd.
Symbiotec Pharmalab Company Address
Symbiotec Pharmalab Ltd.
385/2,
Pigdamber, Rau,
Mhow,
Indore, Madhya Pradesh, 453331
Phone: +91 731 667 6405
Email: secretarial@symbiotec.com
Website: http://www.symbiotec.com/
Symbiotec Pharmalab IPO Registrar
MUFG Intime India Pvt. Ltd.
Phone: 022-49186000
Email: symbiotecpharmalab.ipo@in.mpms.mufg.com
Website: https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Disclaimer
I am not a SEBI-registered Research Analyst, Investment Adviser, or any other SEBI-regulated financial professional. The information provided on this website regarding IPOs, GMP, stock markets, and other financial topics is for educational and informational purposes only.
The content published on this website should not be considered financial advice, investment advice, or a recommendation to buy, sell, or hold any security. Investors should conduct their own research and consult a SEBI-registered financial advisor before making any investment decisions.